BJMHR
British Journal of Medical and Health Research
Journal home page: www.bjmhr.com

Targeting Neurotransmission and Cell Signaling: The Role of In Vitro Studies in Antidepressant Drug Discovery

P Deepthi[1*], P Sailaja[2], Y Prapurnachandra[3]
1.Department of Pharmacology, Ratnam Institute of Pharmacy, Pidathapolur(V), Muthukur(M), SPSR Nellore Dt. 524346 A.P. India.
2.Associate Professor, Department of Pharmacology, Ratnam Institute of Pharmacy, Pidathapolur(V), Muthukur(M), SPSR Nellore Dt. 524346 A.P. India.
3.Professor & Principal, Department of Pharmacology, Ratnam Institute of Pharmacy, Pidathapolur(V), Muthukur(M), SPSR Nellore Dt. 524346 A.P. India.

ABSTRACT

In vitro pharmacological studies play a crucial role in elucidating the molecular and cellular mechanisms underlying the effects of antidepressants on the central nervous system (CNS). These studies employ cellular models, brain tissue samples, and isolated molecular systems to examine drug interactions with key neurotransmitter systems. Critical areas of research include receptor binding assays for serotonin, norepinephrine, and dopamine receptors, as well as inhibition of neurotransmitter reuptake, primarily through serotonin and norepinephrine transporters. Additionally, antidepressants influence enzyme activity, particularly through monoamine oxidase inhibition, and modulate ion channels, such as voltage-gated sodium and potassium channels, affecting neuronal excitability. Further investigations explore the role of antidepressants in promoting neuroplasticity through neurotrophic factors like brain-derived neurotrophic factor (BDNF), which is associated with synaptic remodelling and resilience against stress-induced neuronal damage. Antidepressants also impact intracellular signalling pathways, including the cAMP/PKA, MAPK/ERK, and mTOR pathways, contributing to their therapeutic efficacy. Moreover, in vitro studies facilitate the assessment of oxidative stress modulation and the regulation of stress-related pathways implicated in depression. These insights not only enhance our understanding of antidepressant pharmacology but also pave the way for identifying novel therapeutic targets, ultimately advancing the development of more effective treatments for depression and other mood disorders.

Keywords: Antidepressants, Neurotransmitter transporters, Brain-derived neurotrophic factor (BDNF), Cell signalling pathways, Neuroplasticity.

*Corresponding Author Email: k.deethideepu2002@gmail.com
Received 21 February 2025, Accepted 16 March 2025

Please cite this article as: Deepthi P *et al*., Targeting Neurotransmission and Cell Signaling: The Role of In Vitro Studies in Antidepressant Drug Discovery. British Journal of Medical and Health Research 2025.

INTRODUCTION

Depression is a major global health concern, affecting millions of individuals and significantly contributing to disability and socioeconomic burdens worldwide (1, 2). The World Health Organization (WHO) reports that depression is a leading cause of disability, underscoring the urgent need for effective therapeutic interventions (3). Antidepressant medications play a crucial role in managing depressive disorders by targeting neurotransmitter systems within the central nervous system (CNS), including serotonin, norepinephrine, and dopamine pathways (4,5). Despite the availability of several antidepressant classes, many patients experience suboptimal therapeutic responses, treatment resistance, delayed onset of action, or undesirable side effects, necessitating the exploration of novel pharmacological approaches (6, 7, 8).

The Role of In Vitro Pharmacological Studies in Antidepressant Research

In vitro pharmacological studies provide an essential platform for understanding the mechanisms of antidepressant action, assessing drug efficacy, and evaluating potential safety profiles before progressing to in vivo models and clinical trials (9,10,11). By utilizing neuronal cell lines and primary neuronal cultures, researchers can investigate the interaction of antidepressant compounds with key neurotransmitter systems, receptor dynamics, intracellular signalling cascades, and neuroplasticity-related factors (12,13). These studies allow for precise characterization of how compounds modulate serotonin (5-HT), norepinephrine (NE), and dopamine (DA) neurotransmission, as well as their influence on receptor binding and synaptic plasticity (14,15,16).

Advancements in high-throughput screening (HTS) technologies and the development of innovative assay systems have significantly enhanced the ability to assess the pharmacological profiles of potential antidepressants (17,18). Techniques such as receptor binding assays, neurotransmitter uptake inhibition studies, and enzymatic activity modulation assays (e.g., monoamine oxidase inhibition) provide critical insights into the therapeutic potential of novel compounds (19,20). Additionally, in vitro models help elucidate antidepressants' roles in promoting neurogenesis, modulating stress-response pathways, and regulating brain-derived neurotrophic factor (BDNF), a key mediator of synaptic plasticity and resilience against stress-induced neuronal damage (21,22,23).

Need for Novel Antidepressants and Future Directions

Given the heterogeneity of depression and the limitations of existing treatments, the search for novel, more effective, and faster-acting antidepressants remains a priority in psychiatric research (24,25). In vitro pharmacological investigations provide a crucial foundation for identifying and validating new therapeutic targets, ultimately paving the way for the

development of innovative treatment strategies with improved efficacy and reduced side effects (26,27,28). As research progresses, integrating in vitro findings with in vivo studies and clinical trials will be essential in translating laboratory discoveries into effective, personalized treatment options for depression (29,30).

Current Challenges in Antidepressant Therapy

Although existing antidepressants have been effective for many patients, their limitations necessitate continued research and innovation. Some of the key challenges associated with current antidepressant treatments include:

- **Delayed Onset of Action:** Most conventional antidepressants take several weeks to exert their full therapeutic effects.
- **Incomplete Response:** A significant proportion of patients experience partial relief from symptoms, leading to residual depressive states.
- **Side Effects:** Common side effects, such as weight gain, sexual dysfunction, gastrointestinal disturbances, and increased anxiety, contribute to poor medication adherence.
- **Treatment Resistance:** Up to 30% of patients diagnosed with major depressive disorder (MDD) exhibit treatment-resistant depression, where standard therapies fail to provide adequate relief.

To overcome these challenges, researchers are investigating new pharmacological targets beyond monoaminergic neurotransmission, focusing on neuroplasticity, neuroinflammation, and intracellular signalling pathways.

Role of In Vitro Pharmacological Studies in Antidepressant Research

In vitro pharmacological studies play a crucial role in understanding the mechanisms of action of antidepressants. By using controlled laboratory models, such as neuronal cell lines and primary cultures, researchers can investigate how potential antidepressant compounds interact with neurotransmitter systems, signalling pathways, and cellular functions.

Key Areas of Investigation

Neurotransmitter System Modulation

- Antidepressants primarily target serotonin (5-HT), norepinephrine (NE), and dopamine (DA) pathways. In vitro models allow researchers to examine how specific compounds influence neurotransmitter reuptake, receptor binding, and synaptic activity.
- Receptor binding assays and transporter inhibition studies help determine the efficacy and selectivity of new antidepressant candidates.

Neuroplasticity and Synaptic Remodelling

- Emerging evidence suggests that depression is linked to impaired synaptic plasticity. Antidepressants may promote neurogenesis and synaptic remodelling by increasing brain-derived neurotrophic factor (BDNF) levels.
- In vitro assays help analyze the effects of compounds on dendritic spine formation, neuronal connectivity, and neurotrophic factor expression.

Neuro-inflammation and Immune System Involvement

- Chronic inflammation has been implicated in the pathophysiology of depression. Elevated levels of pro-inflammatory cytokines, such as interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α), are observed in depressed individuals.
- In vitro models allow scientists to assess how antidepressants modulate inflammatory markers and restore immune system balance.

Mitochondrial Function and Oxidative Stress

- Mitochondrial dysfunction and oxidative stress contribute to neuronal damage in depression. Antioxidant properties of antidepressants can be evaluated through in vitro assays measuring reactive oxygen species (ROS) production, mitochondrial membrane potential, and ATP generation.

Intracellular Signalling Pathways

- Antidepressants influence several signalling cascades, including the cAMP/protein kinase A (PKA), mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK), and mammalian target of rapamycin (mTOR) pathways.
- In vitro experiments provide insights into how these pathways regulate neuroplasticity and mood stabilization.

Advancements in In Vitro Screening Technologies

Recent technological innovations have significantly improved the precision and efficiency of in vitro studies in antidepressant research

High-Throughput Screening (HTS):

- HTS enables rapid testing of thousands of compounds for antidepressant activity, accelerating drug discovery efforts.
- Automated screening systems allow for the identification of promising candidates based on their interaction with neurotransmitter receptors and signalling proteins.

Patient-Derived Induced Pluripotent Stem Cells (iPSCs):

- iPSC technology allows researchers to generate patient-specific neuronal models, offering a more personalized approach to studying antidepressant responses.
- By using iPSCs from individuals with depression, scientists can examine drug effects on neurons with unique genetic and epigenetic profiles.

CRISPR/Cas9 Gene Editing:

- CRISPR-based approaches help investigate the role of specific genes in antidepressant response and resistance.
- Gene knockout or modification studies provide valuable insights into novel therapeutic targets.

Future Directions and Implications

In vitro pharmacological research continues to shape the future of antidepressant development. By integrating findings from cellular models with in vivo and clinical studies, researchers can identify more effective, faster-acting, and safer antidepressants. Some promising directions include:

- **Glutamate-Based Therapies:** Exploring NMDA receptor modulators like ketamine and its derivatives, which show rapid antidepressant effects.
- **Neurosteroids and Hormonal Targets:** Investigating the role of allopregnanolone and oestrogen-based therapies in mood regulation.
- **Microbiome and Gut-Brain Axis:** Understanding how gut bacteria influence neurochemistry and mood disorders.

As research progresses, the integration of in vitro studies with computational modeling, artificial intelligence, and biomarker analysis will enhance our ability to develop personalized treatments for depression.

Key Areas of In Vitro Antidepressant Research

1. Neurotransmitter Receptor Binding

Antidepressants primarily exert their effects by modulating neurotransmitter systems within the brain. In vitro studies allow researchers to examine drug interactions with specific receptors involved in mood regulation, including:

Serotonin (5-HT) Receptors:

- SSRIs function by increasing serotonin levels through inhibition of serotonin reuptake transporters (SERT).
- Receptor binding assays help determine how different antidepressants affect serotonin receptor activity.

Norepinephrine (NE) and Dopamine (DA) Receptors:

- SNRIs and some atypical antidepressants influence norepinephrine and dopamine pathways, which play significant roles in motivation, reward, and mood regulation.

GABA and Glutamate Receptors:

- Some antidepressants modulate the balance between inhibitory (GABAergic) and excitatory (glutamatergic) neurotransmission.

- Research on glutamate receptor modulators, such as NMDA receptor antagonists, has revealed promising fast-acting antidepressant effects.

2. Neurotransmitter Uptake Inhibition

Many antidepressants work by preventing the reuptake of neurotransmitters, thereby increasing their availability in the synaptic cleft. In vitro assays commonly used to study this mechanism include:

Radiolabelled Neurotransmitter Assays:

- Measure the ability of antidepressants to block the reuptake of serotonin, norepinephrine, and dopamine.

Transporter Activity Assays:

- Investigate how drugs affect neurotransmitter transport through proteins such as SERT (serotonin transporter) and NET (norepinephrine transporter).

3. Enzyme Inhibition

Certain classes of antidepressants work by inhibiting enzymes responsible for neurotransmitter breakdown, prolonging their activity in the brain. Key enzymes targeted in in vitro studies include:

Monoamine Oxidase (MAO):

- MAO inhibitors (MAOIs) prevent the degradation of serotonin, norepinephrine, and dopamine, enhancing their mood-elevating effects.
- In vitro enzyme inhibition assays help assess the potency and specificity of MAOIs.

Catechol-O-Methyltransferase (COMT):

- COMT is involved in the breakdown of catecholamines, including dopamine and norepinephrine.
- Some antidepressants influence COMT activity, and in vitro studies explore their impact on neurotransmitter metabolism.

4. Signal Transduction Pathways

Antidepressants influence intracellular signalling pathways that regulate neuroplasticity, synaptic function, and neuronal survival. Some key pathways studied in vitro include:

CAMP/PKA Pathway:

- Plays a vital role in synaptic plasticity and neurogenesis.
- Researchers examine how antidepressants influence cyclic adenosine monophosphate (cAMP) levels and protein kinase A (PKA) activity.

MAPK/ERK Signalling:

- Important for neuronal growth and survival.

- In vitro studies assess whether antidepressants activate or modulate mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) pathways.

BDNF Signalling:

- Brain-derived neurotrophic factor (BDNF) is essential for synaptic plasticity and resilience.
- Some antidepressants increase BDNF levels, and receptor activation studies (e.g., TrkB receptor) provide insights into their effects.

5. Neuroplasticity and Neuroprotection

One of the most promising areas of antidepressant research involves their role in promoting neuroplasticity and protecting neurons from damage. In vitro models are used to study:

Neuronal Growth and Synaptic Remodelling:

- Some antidepressants enhance dendritic branching and spine formation in neuronal cultures, supporting their role in synaptic connectivity.

Cell Survival and Stress Resistance:

- Antidepressants may protect neurons from apoptosis (programmed cell death) under conditions of oxidative stress and neuroinflammation.

Inhibition of Neuroinflammation:

- Glial cells (microglia and astrocytes) play an essential role in inflammation-related depression.
- In vitro studies examine how antidepressants modulate inflammatory responses and cytokine production.

6. High-Throughput Screening (HTS) Technologies

Advancements in HTS technologies have significantly accelerated antidepressant discovery. These automated systems allow researchers to screen thousands of compounds for:

Receptor Binding Affinity:

- Determines the selectivity of potential antidepressants for specific neurotransmitter receptors.

Neurotransmitter Transporter Inhibition:

- Measures how effectively a compound blocks the reuptake of serotonin, norepinephrine, and dopamine.

Toxicity and Efficacy Profiling:

- Identifies compounds with promising antidepressant activity while minimizing unwanted side effects.

7. Translating In Vitro Findings to In Vivo Models

While in vitro studies provide valuable insights into antidepressant mechanisms, translating these findings into whole-organism (in vivo) models remains a challenge. Some key limitations include:

Complex Interactions in the Brain:

- In vitro models cannot fully replicate hormonal regulation, blood-brain barrier permeability, and long-term neuronal changes.

Variability in Drug Response:

- Individual differences in genetics and metabolism influence antidepressant efficacy, necessitating complementary in vivo studies.

8. Future Directions and Clinical Implications

As research progresses, the integration of in vitro studies with personalized medicine approaches is becoming increasingly important. Promising future directions include:

Glutamate-Based Therapies:

- NMDA receptor modulators like ketamine have demonstrated rapid antidepressant effects.

Patient-Derived iPSC Models:

- Enable the study of individual drug responses based on genetic and epigenetic factors.

Artificial Intelligence (AI) in Drug Discovery:

- AI-driven models assist in predicting antidepressant efficacy and optimizing drug design.

Neuroplasticity and Neurotrophic Effects

One of the key aspects of antidepressant research focuses on their ability to enhance neuroplasticity and promote neurotrophic effects. These mechanisms are crucial for long-term mood stabilization and recovery from depression. A major area of study involves the regulation of brain-derived neurotrophic factor (BDNF), a protein essential for synaptic plasticity, neuronal survival, and cognitive function. Antidepressants have been found to upregulate BDNF expression, contributing to enhanced neural resilience and adaptive synaptic remodelling.

Cell Signalling Pathways Involved in Antidepressant Action

Antidepressants modulate several intracellular signalling pathways that influence neuronal function and survival. Among the most studied pathways are:

- **cAMP/PKA Pathway:** Plays a role in synaptic plasticity and gene transcription related to neuronal growth.
- **MAPK/ERK Pathway:** Involved in cell proliferation, differentiation, and survival, supporting long-term neuroadaptive changes.

- **mTOR Signalling:** Regulates protein synthesis necessary for synaptic remodelling, particularly in response to rapid-acting antidepressants like ketamine.

Cell Models Used in In Vitro Studies

To investigate the cellular and molecular effects of antidepressants, researchers utilize various **in vitro** models, including:

1. Cultured Neurons or Cell Lines

- Widely used to assess neurotransmitter system interactions, receptor expression, and intracellular signalling in response to antidepressants.

2. Primary Neuronal Cultures

- Derived directly from brain tissue, these cultures provide a more physiologically relevant model to study drug effects on neuroplasticity and ion channel modulation.
- Glial cell cultures are also employed to investigate neuroinflammatory processes and their role in depression.

Techniques Employed in In Vitro Antidepressant Research

A variety of techniques are utilized to assess the pharmacological effects of antidepressants on the central nervous system:

1. Radiolabelled Ligand Binding Assays

- Used to evaluate the binding affinity of antidepressants to specific neurotransmitter receptors, providing insight into their primary targets.

2. Neurotransmitter Uptake Assays

- Measure the ability of antidepressants to inhibit neurotransmitter transporters, such as serotonin (SERT) and norepinephrine (NET) transporters.

3. Western Blotting and Polymerase Chain Reaction (PCR)

- Employed to analyze changes in protein expression, receptor density, and signalling molecule activity following antidepressant treatment.

4. Patch-Clamp and Electrophysiological Recordings

- Allow researchers to study how antidepressants influence neuronal excitability, synaptic transmission, and ion channel activity.

5. ELISA and Immunohistochemistry

- Used to detect and quantify levels of neurotrophic factors like BDNF and intracellular signalling proteins involved in antidepressant response.

Advancements in Drug Development through In Vitro Research

In vitro pharmacological studies provide fundamental data for the identification of novel therapeutic targets and the screening of potential antidepressant compounds. These studies help streamline drug discovery by offering early insights into efficacy, pharmacodynamics,

and potential mechanisms of action. Findings from in vitro research significantly contribute to the design of clinical trials, increasing the likelihood that drugs demonstrating promise in cellular models will be effective in human treatment.

Limitations of In Vitro Studies

While invaluable for understanding drug mechanisms, in vitro studies have several limitations that must be considered:

1. Reduced Biological Complexity

- **Simplified Models:** In vitro studies lack the full physiological context of a living organism, omitting factors such as blood-brain barrier dynamics, immune responses, and metabolic processing.
- **Limited Neuronal Interactions:** These models often consist of isolated cells that do not replicate the intricate network of neuronal and glial interactions found in the CNS.

2. Absence of Behavioural and Cognitive Assessments

- In vitro studies focus on cellular and molecular mechanisms but cannot capture how antidepressants influence mood, cognition, and emotional processing, which are central to clinical depression treatment.
- Depression involves psychological and environmental factors that cannot be replicated in a cell culture system.

3. Inability to Detect Long-Term Adverse Effects

- While in vitro studies provide preliminary toxicity assessments, they cannot fully predict long-term side effects, systemic toxicity, or interactions with other biological processes.
- More complex models, including animal studies and clinical trials, are necessary to evaluate the safety profile of potential antidepressants.

Key Areas of In Vitro Antidepressant Research

1. Neurotransmitter Receptor Binding

Antidepressants primarily exert their effects by modulating neurotransmitter systems within the brain. In vitro studies allow researchers to examine drug interactions with specific receptors involved in mood regulation, including:

Serotonin (5-HT) Receptors:

- SSRIs function by increasing serotonin levels through inhibition of serotonin reuptake transporters (SERT).
- Receptor binding assays help determine how different antidepressants affect serotonin receptor activity.

Norepinephrine (NE) and Dopamine (DA) Receptors:

- SNRIs and some atypical antidepressants influence norepinephrine and dopamine pathways, which play significant roles in motivation, reward, and mood regulation.

GABA and Glutamate Receptors:

- Some antidepressants modulate the balance between inhibitory (GABAergic) and excitatory (glutamatergic) neurotransmission.
- Research on glutamate receptor modulators, such as NMDA receptor antagonists, has revealed promising fast-acting antidepressant effects.

2. Neurotransmitter Uptake Inhibition

Many antidepressants work by preventing the reuptake of neurotransmitters, thereby increasing their availability in the synaptic cleft. In vitro assays commonly used to study this mechanism include:

Radiolabeled Neurotransmitter Assays:

- Measure the ability of antidepressants to block the reuptake of serotonin, norepinephrine, and dopamine.

Transporter Activity Assays:

- Investigate how drugs affect neurotransmitter transport through proteins such as SERT (serotonin transporter) and NET (norepinephrine transporter).

3. Enzyme Inhibition

Certain classes of antidepressants work by inhibiting enzymes responsible for neurotransmitter breakdown, prolonging their activity in the brain. Key enzymes targeted in in vitro studies include:

Monoamine Oxidase (MAO):

- MAO inhibitors (MAOIs) prevent the degradation of serotonin, norepinephrine, and dopamine, enhancing their mood-elevating effects.
- In vitro enzyme inhibition assays help assess the potency and specificity of MAOIs.

Catechol-O-Methyltransferase (COMT):

- COMT is involved in the breakdown of catecholamines, including dopamine and norepinephrine.
- Some antidepressants influence COMT activity, and in vitro studies explore their impact on neurotransmitter metabolism.

4. Signal Transduction Pathways

Antidepressants influence intracellular signalling pathways that regulate neuroplasticity, synaptic function, and neuronal survival. Some key pathways studied in vitro include:

CAMP/PKA Pathway:

- Plays a vital role in synaptic plasticity and neurogenesis.

- Researchers examine how antidepressants influence cyclic adenosine monophosphate (cAMP) levels and protein kinase A (PKA) activity

MAPK/ERK Signalling:

- Important for neuronal growth and survival.
- In vitro studies assess whether antidepressants activate or modulate mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) pathways.

BDNF Signalling:

- Brain-derived neurotrophic factor (BDNF) is essential for synaptic plasticity and resilience.
- Some antidepressants increase BDNF levels, and receptor activation studies (e.g., TrkB receptor) provide insights into their effects.

5. Neuroplasticity and Neuroprotection

One of the most promising areas of antidepressant research involves their role in promoting neuroplasticity and protecting neurons from damage. In vitro models are used to study:

Neuronal Growth and Synaptic Remodelling:

- Some antidepressants enhance dendritic branching and spine formation in neuronal cultures, supporting their role in synaptic connectivity.

Cell Survival and Stress Resistance:

- Antidepressants may protect neurons from apoptosis (programmed cell death) under conditions of oxidative stress and neuroinflammation.

Inhibition of Neuroinflammation:

- Glial cells (microglia and astrocytes) play an essential role in inflammation-related depression.
- In vitro studies examine how antidepressants modulate inflammatory responses and cytokine production.

6. High-Throughput Screening (HTS) Technologies

Advancements in HTS technologies have significantly accelerated antidepressant discovery. These automated systems allow researchers to screen thousands of compounds for:

Receptor Binding Affinity:

- Determines the selectivity of potential antidepressants for specific neurotransmitter receptors.

Neurotransmitter Transporter Inhibition:

- Measures how effectively a compound blocks the reuptake of serotonin, norepinephrine, and dopamine.

Toxicity and Efficacy Profiling:

- Identifies compounds with promising antidepressant activity while minimizing unwanted side effects.

7. Translating In Vitro Findings to In Vivo Models

While in vitro studies provide valuable insights into antidepressant mechanisms, translating these findings into whole-organism (in vivo) models remains a challenge. Some key limitations include:

Complex Interactions in the Brain:

- In vitro models cannot fully replicate hormonal regulation, blood-brain barrier permeability, and long-term neuronal changes.

Variability in Drug Response:

- Individual differences in genetics and metabolism influence antidepressant efficacy, necessitating complementary in vivo studies.

8. Future Directions and Clinical Implications

As research progresses, the integration of in vitro studies with personalized medicine approaches is becoming increasingly important. Promising future directions include:

Glutamate-Based Therapies:

- NMDA receptor modulators like ketamine have demonstrated rapid antidepressant effects.

Patient-Derived iPSC Models:

- Enable the study of individual drug responses based on genetic and epigenetic factors.

Artificial Intelligence (AI) in Drug Discovery:

- AI-driven models assist in predicting antidepressant efficacy and optimizing drug design.

CONCLUSION

In vitro pharmacological studies are instrumental in advancing our understanding of antidepressant mechanisms within the central nervous system. These studies provide essential insights into drug-receptor interactions, neurotransmitter modulation, enzyme activity, and neuroplasticity-related changes. By utilizing cell-based models and cutting-edge molecular techniques, researchers can uncover crucial information about how antidepressants exert their therapeutic effects at the cellular level. Although in vitro models have limitations, they remain a fundamental step in antidepressant drug discovery, guiding subsequent in vivo research and clinical trials. The continued integration of in vitro studies with novel technologies, such as patient-derived stem cells and high-throughput screening, holds great promise for the development of more effective and targeted treatments for depression and

related mood disorders. Ultimately, these studies contribute significantly to the ongoing efforts to improve antidepressant therapies and address the global burden of depression.

REFERENCES

1. World Health Organization (2020). Depression and other common mental disorders: Global health estimates. Geneva: WHO.
2. Kessler, Ronald C., Bromet, Evelyn J. (2018). The global burden of depression: A systematic analysis. The Lancet Psychiatry, 5(2), 113-122.
3. Friedrich, Matthew J. (2017). Depression is the leading cause of disability worldwide. JAMA, 317(15), 1517.
4. Malhi, Gin S., Mann, John J. (2018). Depression. The Lancet, 392(10161), 2299-2312.
5. Delgado, Pedro L. (2000). Depression: The case for a monoamine deficiency. Journal of Clinical Psychiatry, 61(6), 7-11.
6. Rush, A. John, Trivedi, Madhukar H., Wisniewski, Stephen R. (2006). STAR*D: Lessons learned and future directions. American Journal of Psychiatry, 163(11), 1905-1917.
7. Andrade, Chittaranjan (2020). Pharmacotherapy for major depressive disorder: Efficacy and tolerability of antidepressants. Journal of Clinical Psychiatry, 81(3), 19f13153.
8. Cipriani, Andrea, Furukawa, Toshi A., Salanti, Georgia (2018). Comparative efficacy and acceptability of 21 antidepressant drugs. The Lancet, 391(10128), 1357-1366.
9. Hyman, Steven E. (2014). Revitalizing psychiatric therapeutics. Neuropsychopharmacology, 39(1), 220-229.
10. Jaffe, Jerome H., Klein, Donald F. (2012). Drug discovery and antidepressant research. Biological Psychiatry, 72(10), 671-674.
11. Fava, Maurizio, Davidson, Karl G. (2016). Definition and epidemiology of treatment-resistant depression. Psychiatric Clinics, 39(2), 145-162.
12. Castrén, Eero (2013). Neuronal network plasticity and recovery from depression. JAMA Psychiatry, 70(9), 983-989.
13. Nestler, Eric J., Carlezon, William A. (2006). The mesolimbic dopamine reward circuit in depression. Biological Psychiatry, 59(12), 1151-1159.
14. Krishnan, Vaishnav, Nestler, Eric J. (2008). The molecular neurobiology of depression. Nature, 455(7215), 894-902.
15. Berton, Olivier, Nestler, Eric J. (2006). New approaches to antidepressant drug discovery: Beyond monoamines. Nature Reviews Neuroscience, 7(2), 137-151.

16. Sanacora, Gerard, Zarate, Carlos A., Krystal, John H. (2012). Beyond monoamines in antidepressant action: The role of glutamate and GABA. Biological Psychiatry, 71(11), 1171-1180.
17. Zhou, Xiang, Michael, Nora, Smith, Evan M. (2015). High-throughput screening in antidepressant drug discovery. Journal of Neuroscience Methods, 241, 76-82.
18. Monteggia, Lisa M., Luikart, Bryan W., Parada, Luis F. (2013). BDNF signaling in psychiatric disorders. Molecular Psychiatry, 18(8), 834-839.
19. Hasler, Gregor (2010). Pathophysiology of depression: Do we have any solid evidence of interest to clinicians? World Psychiatry, 9(3), 155-161.
20. Hillhouse, Todd M., Porter, James H. (2015). A brief history of the development of antidepressant drugs: From monoamines to glutamate. Experimental and Clinical Psychopharmacology, 23(1), 1-21.
21. Duman, Ronald S., Aghajanian, George K. (2012). Synaptic dysfunction in depression: Potential therapeutic targets. Science, 338(6103), 68-72.
22. Autry, Anita E., Monteggia, Lisa M. (2012). Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacological Reviews, 64(2), 238-258.
23. Zanos, Panos, Moaddel, Ruin, Morris, Peter J. (2016). Ketamine and its metabolite, hydroxynorketamine, sustain antidepressant effects via AMPA receptor activation. Nature, 533(7604), 481-486.
24. Deepthi V, Rao PK, Vasanth PM (2014). Evaluation of therapeutic response of methotrexate and calcipotriol combination compared with methotrexate alone in plaque psoriasis. *Our Dermatol Online*, 5(2), 118-123.
25. Ramya P, Vasanth P M, Prasad P V, Babu S V (2019). Qualitative phytochemical screening tests of Alpinia galanga L. *World Journal of Pharmaceutical Research*, 8(5), 1064-1077.
26. Prasanthi, R. M., Vasanth, P. M., & Ramesh, T. (2013). Assays for oxidative stress and antioxidant status. *Research Journal of Pharmaceutical, Biological and Chemical Sciences*, 4(1), 846-856.
27. Trivedi, Madhukar H., Greer, Tracy L. (2014). Cognitive dysfunction in unipolar depression: Implications for treatment. Journal of Affective Disorders, 152, 19-27.
28. Stahl, Stephen M. (2013). Mechanism of action of serotonin selective reuptake inhibitors: Serotonin receptors and pathways mediate therapeutic effects and side effects. Journal of Affective Disorders, 151(1), 1-15.

29. Menard, Caroline, Pfau, Marie L., Hodes, Georgia E. (2017). Social stress induces neurovascular pathology promoting depression. Nature Neuroscience, 20(12), 1752-1760.
30. Duman, Ronald S., Shinohara, Ryoko (2016). Neurobiology of stress adaptation and the development of stress-related disorders. Nature Medicine, 22(9), 994-1002.
31. Krystal, John H., Sanacora, Gerard, Duman, Ronald S. (2019). Rapid-acting glutamatergic antidepressants: The path to ketamine and beyond. Biological Psychiatry, 86(5), 388-402.
32. Berton, Olivier, Hahn, Changsoo G., Thase, Michael E. (2012). Are we getting closer to personalized treatments for depression? A neurobiological perspective. Nature Reviews Neuroscience, 13(8), 547-560.
33. Lépine, Jean-Pierre, Briley, Mike (2011). The increasing burden of depression. Neuropsychiatric Disease and Treatment, 7(1), 3-7.
34. Hollon, Steven D., DeRubeis, Robert J., Shelton, Richard C. (2005). Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Archives of General Psychiatry, 62(4), 417-422.
35. Malberg, Jessica E., Eisch, Amelia J., Nestler, Eric J. (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. Journal of Neuroscience, 20(24), 9104-9110.
36. Castrén, Eero, Hen, René (2013). Neuronal plasticity and antidepressant actions. Trends in Neurosciences, 36(5), 259-267.
37. Maeng, Sungho, Zarate, Carlos A. (2007). The role of glutamate in mood disorders: Results from preclinical and clinical studies. Biological Psychiatry, 61(8), 856-867.
38. Sartorius, Norman, Schulze, Hinrich (2015). Reducing the stigma of mental illness: A report from a global programme of the World Psychiatric Association. Cambridge University Press.
39. Meyer, Jerrold H., Wilson, Andrea A., Sagrati, Samantha (2001). Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses. American Journal of Psychiatry, 158(11), 1843-1849.
40. Nemeroff, Charles B. (2007). The burden of severe depression: A review of diagnostic challenges and treatment alternatives. Journal of Psychiatric Research, 41(3-4), 189-206.
41. Cusin, Cristina, Dougherty, Darin D. (2012). Somatic therapies for treatment-resistant depression: ECT, TMS, VNS, DBS. Biological Psychiatry, 71(12), 1096-1107.

42. Richelson, Elliot (2003). Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. Journal of Clinical Psychiatry, 64(Suppl 13), 5-12.